Advertisement

European Journal of Epidemiology

, Volume 28, Issue 4, pp 359–360 | Cite as

Gout and the risk of Parkinson’s disease in Denmark

  • Eva Schernhammer
  • Jiaheng Qiu
  • Lene Wermuth
  • Christina Funch Lassen
  • Soren Friis
  • Beate Ritz
Letter to the Editor

There is growing evidence that oxidative stress plays a major role in Parkinson’s disease (PD) etiology [1, 2]. Importantly, uric acid has been shown in experimental studies to have an antioxidant effect on neurons [3, 4]. Recently, several observational studies have also evaluated associations between serum uric acid levels and PD risk and have consistently reported a lower risk of PD among individuals with the highest levels of serum uric acid [5, 6, 7, 8, 9, 10]. The most common metabolic disorder underlying hyper uricemia is gout. Thus, if hyperuricemia decreases the risk of PD, gout should also be negatively associated with PD risk. Two studies, to date, have evaluated the association between gout and PD risk and both reported an inverse association [11, 12], although the association was only observed among men in one of the two studies [11].

Using Danish population registers, we aimed to confirm the findings from these two previous observational studies. We investigated whether a...

Keywords

Chronic Obstructive Pulmonary Disease Uric Acid Gout Serum Uric Acid Hyperuricemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This study was supported by a grant from the National Institutes of Environmental Health Sciences, USA (Grant No. R01 ES013717). Partial funding was also provided by the National Institutes of Neurologic Diseases and Stroke, USA for the UCLA Udall Parkinson Disease Center of Excellence Grant No. P50 NS038367). The funding source had no role in the design or analysis of the study or in the decision to submit the manuscript for publication.

References

  1. 1.
    Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem. 2010;345(1–2):91–104.PubMedCrossRefGoogle Scholar
  2. 2.
    Kyrozis A, Ghika A, Stathopoulos P, Vassilopoulos D, Trichopoulos D, Trichopoulou A. Dietary and lifestyle variables in relation to incidence of Parkinson’s disease in Greece. Eur J Epidemiol 2013. doi: 10.1007/s10654-012-9760-0.
  3. 3.
    Church WH, Ward VL. Uric acid is reduced in the substantia nigra in Parkinson’s disease: effect on dopamine oxidation. Brain Res Bull. 1994;33(4):419–25.PubMedCrossRefGoogle Scholar
  4. 4.
    Tohgi H, Abe T, Takahashi S, Kikuchi T. The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson’s disease. J Neural Transm Park Dis Dement Sect. 1993;6(2):119–26.PubMedCrossRefGoogle Scholar
  5. 5.
    Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson’s disease. Am J Epidemiol. 1996;144(5):480–4.PubMedCrossRefGoogle Scholar
  6. 6.
    de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol. 2005;58(5):797–800.PubMedCrossRefGoogle Scholar
  7. 7.
    Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson’s disease. Am J Epidemiol. 2007;166(5):561–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Larumbe Ilundain R, Ferrer Valls JV, Vines Rueda JJ, Guerrero D, Fraile P. Case-control study of markers of oxidative stress and metabolism of blood iron in Parkinson’s disease. Rev Esp Salud Publica. 2001;75(1):43–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Annanmaki T, Muuronen A, Murros K. Low plasma uric acid level in Parkinson’s disease. Mov Disord. 2007;22(8):1133–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson’s disease risk, diagnosis and prognosis. Biomark Med. 2010;4(5):701–12.PubMedCrossRefGoogle Scholar
  11. 11.
    Alonso A, Rodriguez LA, Logroscino G, Hernan MA. Gout and risk of Parkinson disease: a prospective study. Neurology. 2007;69(17):1696–700.PubMedCrossRefGoogle Scholar
  12. 12.
    De Vera M, Rahman MM, Rankin J, Kopec J, Gao X, Choi H. Gout and the risk of Parkinson’s disease: a cohort study. Arthritis Rheum. 2008;59(11):1549–54.PubMedCrossRefGoogle Scholar
  13. 13.
    Lynge E, Sandegaard JL, Rebolj M. The danish national patient register. Scand J Public Health. 2011;39(7 Suppl):30–3.PubMedCrossRefGoogle Scholar
  14. 14.
    Pedersen CB. The danish civil registration system. Scand J Public Health. 2011;39(7 Suppl):22–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B. Diabetes and the risk of developing Parkinson’s disease in Denmark. Diabetes Care. 2011;34(5):1102–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Eva Schernhammer
    • 1
    • 2
    • 3
    • 7
  • Jiaheng Qiu
    • 4
  • Lene Wermuth
    • 5
  • Christina Funch Lassen
    • 6
  • Soren Friis
    • 6
  • Beate Ritz
    • 4
  1. 1.Channing Division of Network Medicine, Department of MedicineHarvard Medical SchoolBostonUSA
  2. 2.Department of EpidemiologyHarvard School of Public HealthBostonUSA
  3. 3.LBI-ACR and ACR-ITR VIEnna/CEADDPViennaAustria
  4. 4.Department of EpidemiologyUCLA School of Public HealthLos AngelesUSA
  5. 5.Department of NeurologyOdense University HospitalOdenseDenmark
  6. 6.Danish Cancer Society Research CenterDanish Cancer SocietyCopenhagenDenmark
  7. 7.Channing Division of Network MedicineBostonUSA

Personalised recommendations